希斯皮杜林向PTGS2,通过抑制NLRP3炎症酶来改善循环胺诱导的囊炎
Songlin Liu1, Shuhang Li1, Yuping Dong2
1Department of Urology, Yantai Affiliated Hospital of Binzhou Medical University, Yantai, 264000, China.
Naunyn-Schmiedeberg's archives of pharmacology
|February 6, 2024
概括
在间歇性囊炎 (IC) 模型中,希斯皮杜林通过抑制PTGS2和NLRP3通路,有效地减少炎症和膀疼痛. 这表明希斯皮杜林是IC的潜在新疗法.
科学领域:
- 药理学 药理学是指药理学的学科.
- 免疫学 免疫学 免疫学
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
背景情况:
- 间歇性囊炎 (IC) 是一种慢性膀炎症状况.
- 抑制前列腺素G/H合成酶2 (PTGS2) 是一种常见的抗炎症策略.
- PTGS2和NLRP3炎症酶在IC病原发生中的作用需要进一步研究.
研究的目的:
- 在实验性IC模型中研究希斯皮杜林对PTGS2和NLRP3炎症组的影响.
- 评估hispidulin作为IC的替代治疗剂的潜力.
主要方法:
- 用分子对接来评估hispidulin和PTGS2.2之间的结合活性.
- 试验室研究涉及用IL-1β和各种度的希斯皮杜林治疗人类尿细胞 (SV-HUC-1).
- 在体内研究中使用了循环胺 (CYP) 诱导的IC大鼠模型,用希斯皮杜林或布洛芬治疗.
主要成果:
- 希斯皮杜林表现出与PTGS2.2具有良好的结合活性.
- 希斯皮杜林在体外以剂量依赖的方式显著降低了PTGS2和NLRP3炎症酶表达.
- 希斯皮杜林在体内缓解了膀疼痛,并抑制了PTGS2和NLRP3炎症酶表达,与布洛芬相似.
结论:
- 希斯皮杜林通过抑制PTGS2和NLRP3炎症酶来表现出抗炎作用.
- 在实验性IC模型中,希斯皮杜林有效减少疼痛和膀病理.
- 希斯皮杜林显示出作为一种新的治疗候选人的承诺,用于间歇性囊炎.
相关概念视频
Drugs for Treatment of Constipation-Predominant IBS
169
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
169
Drugs for Treatment of Ulcerative Colitis in IBD
141
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
141
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
166
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
166
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
437
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
437
Drugs for Treatment of Diarrhea-Predominant IBS
175
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
175
Inflammatory Bowel Disease IV: Pharmacological Management
127
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
127


